外泌体疗法市场－全球产业规模、份额、趋势、机会和预测，按外泌体类型、来源、疗法、应用、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球外泌体疗法市场规模为3,263万美元，预计2030年将以41.56%的复合年增长率成长至2.6258亿美元。外泌体疗法利用天然存在的细胞来源奈米囊泡，促进细胞间通讯并将生物活性分子递送至目标细胞，为多种疾病的治疗开闢了新的途径。市场扩张的根本动力在于人们对胞外体生物学认识的不断加深、慢性病和老年相关疾病日益普遍（需要更先进的治疗方法）以及对生物技术研发的大量投资。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球外泌体疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依外泌体类型（天然型、混合型）
  • 依来源分类（间质干细胞、血液、体液、其他）
  • 依治疗方法（免疫疗法、化学疗法、基因疗法）
  • 依应用领域（代谢性疾病、肿瘤、心臟疾病、神经病学、其他）
  • 按最终用户（医院和诊所、学术和研究机构、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美外泌体疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲外泌体疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区外泌体疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲外泌体疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲外泌体疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球外泌体疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Aethlon Medical, Inc.
• AEGLE Therapeutics Corporation
• Anjarium Biosciences AG
• Exogenus Therapeutics SA
• Lonza Group AG
• Capricor Therapeutics Inc
• Avalon GloboCare Corp.
• Stem Cell Medicine Ltd.
• Evox Therapeutics Limited.
• EV Therapeutics

第十六章：策略建议

第17章调查会社について・免责事项

The Global Exosome Therapeutics Market, valued at USD 32.63 Million in 2024, is projected to experience a CAGR of 41.56% to reach USD 262.58 Million by 2030. Exosome therapeutics involve the utilization of naturally occurring, cell-derived nanovesicles that facilitate intercellular communication and deliver bioactive molecules to target cells, presenting novel therapeutic avenues for various diseases. The market's expansion is fundamentally supported by an escalating understanding of exosome biology, the increasing prevalence of chronic and age-related conditions necessitating advanced treatment modalities, and substantial investment in biotechnology research and development

Key Market Drivers

The increasing incidence of chronic diseases, particularly cancer, serves as a significant driver for the global exosome therapeutics market. Exosomes offer novel therapeutic avenues through their natural ability to facilitate targeted drug delivery and enable minimally invasive diagnostics, addressing limitations of current treatments. This escalating disease burden necessitates innovative solutions that exosomes are uniquely positioned to provide, aiming for improved efficacy and reduced systemic toxicity. According to the International Agency for Research on Cancer, in 2022, there were close to 20 million new cases of cancer worldwide, highlighting the pressing need for advanced therapeutic strategies and emphasizing the expansive patient population that exosome-based therapies could potentially benefit.

Key Market Challenges

The complexity and cost associated with the large-scale manufacturing and purification of clinical-grade exosomes represent a significant impediment to the expansion of the global exosome therapeutics market. Achieving the necessary purity and quantity of exosomes for clinical applications demands sophisticated and resource-intensive processes, which drives up production expenses. This directly hampers the market by delaying the progression of promising therapies from research and development into commercialization. The intricate nature of isolating and purifying exosomes to meet stringent regulatory standards often results in lower yields and higher per-dose costs, making advanced exosome-based treatments less accessible and financially viable for wider adoption.

Key Market Trends

This involves actively modifying exosomes to enhance their intrinsic capabilities for precise drug delivery and increased therapeutic efficacy, moving beyond their natural properties. Companies are increasingly focusing on engineering exosomes to carry specific payloads directly to disease sites, thereby improving treatment outcomes and minimizing off-target effects. For example, Minovacca, a startup incorporated in January 2025, commercializes universal milk exosomes by chemically and genetically engineering them for target-specific delivery of therapeutics, highlighting this directed approach. This scientific progression is underpinned by extensive collaborative efforts; according to the International Society for Extracellular Vesicles (ISEV), its MISEV2023 guidelines, published in December 2023, incorporated feedback from over 1000 researchers worldwide to standardize and advance exosome research methods, a foundational step for effective exosome engineering.

Key Market Players

• Aethlon Medical, Inc.
• AEGLE Therapeutics Corporation
• Anjarium Biosciences AG
• Exogenus Therapeutics SA
• Lonza Group AG
• Capricor Therapeutics Inc
• Avalon GloboCare Corp.
• Stem Cell Medicine Ltd.
• Evox Therapeutics Limited.
• EV Therapeutics

Report Scope:

In this report, the Global Exosome Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Exosome Therapeutics Market, By Exosome Type:

• Natural
• Hybrid

Exosome Therapeutics Market, By Source:

• Mesenchymal Stem Cells
• Blood
• Body Fluids
• Others

Exosome Therapeutics Market, By Therapy:

• Immunotherapy
• Chemotherapy
• Gene Therapy

Exosome Therapeutics Market, By Application:

• Metabolic Disorders
• Oncology
• Cardiac Disorders
• Neurology
• Others

Exosome Therapeutics Market, By End User:

• Hospitals & Clinics
• Academic & Research Institutions
• Others

Exosome Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Exosome Therapeutics Market.

Available Customizations:

Global Exosome Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Exosome Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Exosome Type (Natural, Hybrid)
  • 5.2.2. By Source (Mesenchymal Stem Cells, Blood, Body Fluids, Others)
  • 5.2.3. By Therapy (Immunotherapy, Chemotherapy, Gene Therapy)
  • 5.2.4. By Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Others)
  • 5.2.5. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Exosome Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Exosome Type
  • 6.2.2. By Source
  • 6.2.3. By Therapy
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Exosome Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Exosome Type
      • 6.3.1.2.2. By Source
      • 6.3.1.2.3. By Therapy
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Exosome Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Exosome Type
      • 6.3.2.2.2. By Source
      • 6.3.2.2.3. By Therapy
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Exosome Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Exosome Type
      • 6.3.3.2.2. By Source
      • 6.3.3.2.3. By Therapy
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Exosome Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Exosome Type
  • 7.2.2. By Source
  • 7.2.3. By Therapy
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Exosome Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Exosome Type
      • 7.3.1.2.2. By Source
      • 7.3.1.2.3. By Therapy
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Exosome Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Exosome Type
      • 7.3.2.2.2. By Source
      • 7.3.2.2.3. By Therapy
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Exosome Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Exosome Type
      • 7.3.3.2.2. By Source
      • 7.3.3.2.3. By Therapy
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Exosome Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Exosome Type
      • 7.3.4.2.2. By Source
      • 7.3.4.2.3. By Therapy
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Exosome Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Exosome Type
      • 7.3.5.2.2. By Source
      • 7.3.5.2.3. By Therapy
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Exosome Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Exosome Type
  • 8.2.2. By Source
  • 8.2.3. By Therapy
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Exosome Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Exosome Type
      • 8.3.1.2.2. By Source
      • 8.3.1.2.3. By Therapy
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Exosome Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Exosome Type
      • 8.3.2.2.2. By Source
      • 8.3.2.2.3. By Therapy
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Exosome Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Exosome Type
      • 8.3.3.2.2. By Source
      • 8.3.3.2.3. By Therapy
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Exosome Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Exosome Type
      • 8.3.4.2.2. By Source
      • 8.3.4.2.3. By Therapy
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Exosome Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Exosome Type
      • 8.3.5.2.2. By Source
      • 8.3.5.2.3. By Therapy
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Exosome Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Exosome Type
  • 9.2.2. By Source
  • 9.2.3. By Therapy
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Exosome Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Exosome Type
      • 9.3.1.2.2. By Source
      • 9.3.1.2.3. By Therapy
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Exosome Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Exosome Type
      • 9.3.2.2.2. By Source
      • 9.3.2.2.3. By Therapy
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Exosome Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Exosome Type
      • 9.3.3.2.2. By Source
      • 9.3.3.2.3. By Therapy
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Exosome Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Exosome Type
  • 10.2.2. By Source
  • 10.2.3. By Therapy
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Exosome Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Exosome Type
      • 10.3.1.2.2. By Source
      • 10.3.1.2.3. By Therapy
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Exosome Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Exosome Type
      • 10.3.2.2.2. By Source
      • 10.3.2.2.3. By Therapy
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Exosome Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Exosome Type
      • 10.3.3.2.2. By Source
      • 10.3.3.2.3. By Therapy
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Exosome Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Aethlon Medical, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AEGLE Therapeutics Corporation
• 15.3. Anjarium Biosciences AG
• 15.4. Exogenus Therapeutics SA
• 15.5. Lonza Group AG
• 15.6. Capricor Therapeutics Inc
• 15.7. Avalon GloboCare Corp.
• 15.8. Stem Cell Medicine Ltd.
• 15.9. Evox Therapeutics Limited.
• 15.10. EV Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer